# Extendicare Policy Manual

## Infection Prevention and Control

- **INDEX:** IPC6-P10
- **SECTION:** Multi-Drug-Resistant Organisms (MDROs)
- **DESCRIPTION:** Multi-Drug-Resistant Organisms (MDROs)
- **EFFECTIVE DATE:** February 18, 2025
- **REVIEWED DATE:** February 11, 2025
- **MODIFIED DATE:** May 30, 2025
- **APPROVED BY:** Chief Medical Officer

----

## POLICY

Screening, surveillance, management, and reporting of Multi-Drug-Resistant Organisms (MDROs) will take place according to provincial/regional requirements. These practices will apply to colonized and infected cases.

## STANDARD

- Follow provincial/regional requirements for the screening, surveillance, management, and reporting of Multi-Drug-Resistant Organisms (MDROs).
- Routine decolonization is not recommended.
- Review antimicrobial use and infection rates regularly to determine if changes in practice are needed to reduce antibiotic-resistant infections.
- The IPAC - MDROs Screening Tool (Multi Drug Resistant Organism) in PCC will be completed within 24 hours of admission or readmission from hospital where stay was greater than 12 hours.

## PROCEDURE

1. IPC6-O10.01 - Multi-Drug-Resistant Organisms (MDROs)
2. IPC6-O10.02 - Vancomycin-Resistant Enterococci (VRE)
3. IPC6-O10.03 - Methicillin-Resistant Staphylococcus Aureus (MRSA)
4. IPC6-O10.04 - Extended-Spectrum Beta-Lactamase (ESBL)
5. IPC6-O10.05 - Carbapenemase-producing Enterobacteriales (CPE)
6. IPC6-O10.06 - Candida auris
7. IPC6-O10.07 - Antimicrobial Stewardship
8. IPC6-O10.08 - Clostridioides difficile

## EDUCATION

1. IPC6-P10-E1 - MDRO Guide
2. IPC6-P10-E2 - Vancomycin Resistant Enterococci (VRE) Fact Sheet
3. IPC6-P10-E3 - Methicillin Resistant Staphylococcus aureus (MRSA) Fact Sheet
4. IPC6-P10-E4 - Extended Spectrum Beta Lactamase (ESBL) Fact Sheet
5. IPC6-P10-E5 - Carbapenemase Producing Enterobacterales (CPE) Fact Sheet
6. IPC6-P10-E6 - Candida auris (C. auris) Fact Sheet
7. IPC6-P10-E7 - Clostridioides difficile (C. difficile) Fact Sheet

## TOOLS

1. IPC6-P10-T1 - MDRO Screening Tool
2. IPC6-P10-T2 - MDRO Risk Assessment Tool
3. IPC6-P10-T3 - Multi-Drug-Resistant Organism (MDRO) Screening Algorithm
4. IPC6-P10-T4 - Multi-Drug-Resistant Organism (MDRO) Tracking Sheet

----

Helping people live better

This document is uncontrolled when printed. Extendicare (Canada) Inc. will provide, on request, information in an accessible format or with communication supports to people with disabilities, in a manner that takes into account their disability. Confidential and Proprietary Information of Extendicare (Canada) Inc. © 2025

----

Page 1 of 2

# POLICY

## SECTION: Multi-Drug-Resistant Organisms (MDROs)

### DESCRIPTION: Multi-Drug-Resistant Organisms (MDROs)

### INDEX: IPC6-P10

1. **IPC6-P10-T5** - Testing Program for Multi-Drug-Resistant Organism (MDRO) Algorithm
2. **IPC6-P10-T6** - CPE Risk Assessment

## REFERENCES

1. Alberta Health Services – Additional Precautions for ARO Positive Residents in Continuing Care in Addition to Routine Practices
Link

2. Antimicrobial Stewardship in Long Term Care | Public Health Ontario

3. Manitoba Health. (2018). Guidelines for the Prevention and Control of Antimicrobial-Resistant Organisms

4. Manitoba Health. Manitoba Health, Seniors and Active Living ARO Definitions

5. Public Health Agency of Canada: Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings – Carbapenem-resistant Gram-negative Bacilli
Link

6. Public Health Ontario – Frequently Asked Questions Carbapenemase-Producing Enterobacteriaceae (CPE)
Link

7. Public Health Ontario – Provincial Infectious Diseases Advisory Committee (PIDAC): Annex A – Screening, Testing and Surveillance for Antibiotic-Resistant Organisms (ARO) February 2013
Link

----

Helping people live better

This document is uncontrolled when printed. Extendicare (Canada) Inc. will provide, on request, information in an accessible format or with communication supports to people with disabilities, in a manner that takes into account their disability. Confidential and Proprietary Information of Extendicare (Canada) Inc. © 2025

----

Page 2 of 2